<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:57:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7461169" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7461169</identifier>
        <datestamp>2020-09-02</datestamp>
        <setSpec>pheblackwell</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="fsb220956" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">FASEB J</journal-id>
              <journal-id journal-id-type="iso-abbrev">FASEB J</journal-id>
              <journal-id journal-id-type="doi">10.1096/(ISSN)1530-6860</journal-id>
              <journal-id journal-id-type="publisher-id">FSB2</journal-id>
              <journal-title-group>
                <journal-title>The FASEB Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0892-6638</issn>
              <issn pub-type="epub">1530-6860</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7461169</article-id>
              <article-id pub-id-type="pmcid">PMC7461169</article-id>
              <article-id pub-id-type="pmc-uid">7461169</article-id>
              <article-id pub-id-type="pmid">32856766</article-id>
              <article-id pub-id-type="pmid">32856766</article-id>
              <article-id pub-id-type="doi">10.1096/fj.202001700RR</article-id>
              <article-id pub-id-type="publisher-id">FSB220956</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Clinical sensitivity and interpretation of PCR and serological COVID‚Äê19 diagnostics for patients presenting to the hospital</article-title>
                <alt-title alt-title-type="left-running-head">MILLER et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="fsb220956-cr-0001" contrib-type="author">
                  <name>
                    <surname>Miller</surname>
                    <given-names>Tyler E.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0002" contrib-type="author">
                  <name>
                    <surname>Garcia Beltran</surname>
                    <given-names>Wilfredo F.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0003" contrib-type="author">
                  <name>
                    <surname>Bard</surname>
                    <given-names>Adam Z.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0004" contrib-type="author">
                  <name>
                    <surname>Gogakos</surname>
                    <given-names>Tasos</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0005" contrib-type="author">
                  <name>
                    <surname>Anahtar</surname>
                    <given-names>Melis N.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0006" contrib-type="author">
                  <name>
                    <surname>Astudillo</surname>
                    <given-names>Michael Gerino</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0007" contrib-type="author">
                  <name>
                    <surname>Yang</surname>
                    <given-names>Diane</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0008" contrib-type="author">
                  <name>
                    <surname>Thierauf</surname>
                    <given-names>Julia</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0009" contrib-type="author">
                  <name>
                    <surname>Fisch</surname>
                    <given-names>Adam S.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0010" contrib-type="author">
                  <name>
                    <surname>Mahowald</surname>
                    <given-names>Grace K.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0011" contrib-type="author">
                  <name>
                    <surname>Fitzpatrick</surname>
                    <given-names>Megan J.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0012" contrib-type="author">
                  <name>
                    <surname>Nardi</surname>
                    <given-names>Valentina</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0013" contrib-type="author">
                  <name>
                    <surname>Feldman</surname>
                    <given-names>Jared</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0014" contrib-type="author">
                  <name>
                    <surname>Hauser</surname>
                    <given-names>Blake M.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0015" contrib-type="author">
                  <name>
                    <surname>Caradonna</surname>
                    <given-names>Timothy M.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0016" contrib-type="author">
                  <name>
                    <surname>Marble</surname>
                    <given-names>Hetal D.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0017" contrib-type="author">
                  <name>
                    <surname>Ritterhouse</surname>
                    <given-names>Lauren L.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0018" contrib-type="author">
                  <name>
                    <surname>Turbett</surname>
                    <given-names>Sara E.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0019" contrib-type="author">
                  <name>
                    <surname>Batten</surname>
                    <given-names>Julie</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0020" contrib-type="author">
                  <name>
                    <surname>Georgantas</surname>
                    <given-names>Nicholas Zeke</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0021" contrib-type="author">
                  <name>
                    <surname>Alter</surname>
                    <given-names>Galit</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0022" contrib-type="author">
                  <name>
                    <surname>Schmidt</surname>
                    <given-names>Aaron G.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0023" contrib-type="author">
                  <name>
                    <surname>Harris</surname>
                    <given-names>Jason B.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0024" contrib-type="author">
                  <name>
                    <surname>Gelfand</surname>
                    <given-names>Jeffrey A.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0025" contrib-type="author">
                  <name>
                    <surname>Poznansky</surname>
                    <given-names>Mark C.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0026" contrib-type="author">
                  <name>
                    <surname>Bernstein</surname>
                    <given-names>Bradley E.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0027" contrib-type="author">
                  <name>
                    <surname>Louis</surname>
                    <given-names>David N.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0028" contrib-type="author">
                  <name>
                    <surname>Dighe</surname>
                    <given-names>Anand</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0029" contrib-type="author">
                  <name>
                    <surname>Charles</surname>
                    <given-names>Richelle C.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0030" contrib-type="author">
                  <name>
                    <surname>Ryan</surname>
                    <given-names>Edward T.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0031" contrib-type="author">
                  <name>
                    <surname>Branda</surname>
                    <given-names>John A.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0032" contrib-type="author">
                  <name>
                    <surname>Pierce</surname>
                    <given-names>Virginia M.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb220956-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0033" contrib-type="author">
                  <name>
                    <surname>Murali</surname>
                    <given-names>Mandakolathur R.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb220956-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0034" contrib-type="author">
                  <name>
                    <surname>Iafrate</surname>
                    <given-names>A. John</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0035" contrib-type="author">
                  <name>
                    <surname>Rosenberg</surname>
                    <given-names>Eric S.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb220956-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb220956-cr-0036" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lennerz</surname>
                    <given-names>Jochen K.</given-names>
                  </name>
                  <xref rid="fsb220956-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>jlennerz@partners.org</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="fsb220956-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pathology</named-content>
                <institution>Massachusetts General Hospital/Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb220956-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Ragon Institute of MGH, MIT, and Harvard</institution>
                <city>Cambridge</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb220956-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Infectious Diseases</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Massachusetts General Hospital/Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb220956-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Division of Infectious Diseases</named-content>
                <named-content content-type="organisation-division">Department of Pediatrics</named-content>
                <institution>Massachusetts General Hospital/Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb220956-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Allergy and Immunology</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Massachusetts General Hospital/Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jochen Lennerz, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.<break/>
Email: at <email>jlennerz@partners.org</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>28</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>34</volume>
              <issue seq="610">10</issue>
              <issue-id pub-id-type="doi">10.1096/fsb2.v34.10</issue-id>
              <fpage>13877</fpage>
              <lpage>13884</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>04</day>
                  <month>8</month>
                  <year>2020</year>
                </date>
                <date date-type="received">
                  <day>09</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>07</day>
                  <month>8</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2020 Federation of American Societies for Experimental Biology-->
                <copyright-statement content-type="article-copyright">¬© 2020 Massachusetts General Hospital, Center for Integrated Diagnostics. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:FSB2-34-13877.pdf"/>
              <abstract id="fsb220956-abs-0001">
                <title>Abstract</title>
                <p>The diagnosis of COVID‚Äê19 requires integration of clinical and laboratory data. Severe acute respiratory syndrome coronavirus 2 (SARS‚ÄêCoV‚Äê2) diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS‚ÄêCoV‚Äê2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital. We conducted a single‚Äêcenter, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR‚Äêpositive SARS‚ÄêCoV‚Äê2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. Clinical sensitivity of PCR decreased with days post symptom onset with &gt;90% clinical sensitivity during the first 5¬†days after symptom onset, 70%‚Äê71% from Days 9 to 11, and 30% at Day 21. To calculate daily clinical sensitivity by serology, we utilized 157 PCR‚Äêpositive patients with a total of 197 specimens tested by enzyme‚Äêlinked immunosorbent assay for IgM, IgG, and IgA anti‚ÄêSARS‚ÄêCoV‚Äê2 antibodies. In contrast to PCR, serological sensitivity increased with days post symptom onset with &gt;50% of patients seropositive by at least one antibody isotype after Day 7, &gt;80% after Day 12, and 100% by Day 21. Taken together, PCR and serology are complimentary modalities that require time‚Äêdependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="fsb220956-kwd-0001">biomarker</kwd>
                <kwd id="fsb220956-kwd-0002">COVID</kwd>
                <kwd id="fsb220956-kwd-0003">qPCR</kwd>
                <kwd id="fsb220956-kwd-0004">SARS‚ÄêCoV‚Äê2</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000060</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>AI146779</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIH
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>RO1 CA225655</award-id>
                  <award-id>R01 AI146779</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>Centers for Disease Control and Prevention
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000030</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U01CK000490</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIGMS
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000057</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>GM007753</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="2"/>
                <page-count count="8"/>
                <word-count count="10655"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>October 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:12.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="fsb220956-cit-1001"><string-name><surname>Miller</surname><given-names>TE</given-names></string-name>, <string-name><surname>Garcia Beltran</surname><given-names>WF</given-names></string-name>, <string-name><surname>Bard</surname><given-names>AZ</given-names></string-name>, et al. <article-title>Clinical sensitivity and interpretation of PCR and serological COVID‚Äê19 diagnostics for patients presenting to the hospital</article-title>. <source>The FASEB Journal</source>. <year>2020</year>;<volume>34</volume>:<fpage>13877</fpage>‚Äì<lpage>13884</lpage>. <pub-id pub-id-type="doi">10.1096/fj.202001700RR</pub-id>
<pub-id pub-id-type="pmid">32856766</pub-id></mixed-citation>
              </p>
              <fn-group id="fsb220956-ntgp-0001">
                <fn fn-type="equal" id="fsb220956-note-0001">
                  <p>Tyler E. Miller, Wilfredo F. Garcia Beltran, Adam Z. Bard, Tasos Gogakos contributed equally to this study.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="fsb220956-body-0001">
            <def-list list-content="abbreviations" id="fsb220956-lp-0001">
              <title>Abbreviations</title>
              <def-item>
                <term>ELISA</term>
                <def>
                  <p>enzyme‚Äêlinked immunosorbent assay</p>
                </def>
              </def-item>
              <def-item>
                <term>RBD</term>
                <def>
                  <p>receptor binding domain</p>
                </def>
              </def-item>
              <def-item>
                <term>SARS‚ÄêCoV‚Äê2</term>
                <def>
                  <p>severe acute respiratory syndrome coronavirus 2</p>
                </def>
              </def-item>
            </def-list>
            <sec id="fsb220956-sec-0001">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>While many measures to mitigate the multifactorial impact of COVID‚Äê19 are being implemented, one critical component of this strategy is the widespread testing and identification of individuals currently or previously infected by severe acute respiratory syndrome coronavirus 2 (SARS‚ÄêCoV‚Äê2). The delivery of effective care and mitigation of infection depend on the performance of SARS‚ÄêCoV‚Äê2 diagnostic testing and the clinical interpretation of results. The lack of a full understanding of the natural history and immunopathogenesis of COVID‚Äê19 infection creates unique challenges in the implementation of diagnostic testing strategies. SARS‚ÄêCoV‚Äê2 diagnostic assays have fixed technical performance metrics (eg, sensitivity and specificity). Clinical sensitivity depends on more than technical performance and is also a function of pre‚Äêanalytical variables and the disease state of the patient. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges.</p>
              <p>The goal of this study is to examine the clinical sensitivity and provide insights into the interpretation of¬†the two most common SARS‚ÄêCoV‚Äê2 diagnostic test modalities: polymerase chain reaction (PCR) and serology. Laboratory‚Äêbased diagnosis of active SARS‚ÄêCoV‚Äê2 infection relies on the direct detection of virus‚Äêspecific nucleic acids, most commonly obtained from the nasopharynx of infected patients. Indirect markers of infection include the detection of SARS‚ÄêCoV‚Äê2 specific antibodies, generated as part of the human immune response to the virus. Serologic testing holds promise as a blood‚Äêbased diagnostic aid, as a marker of viral exposure, and potentially as an indicator of protective immunity. Understanding the presence of these biomarker in relationship to one another over the natural course of infection is required to effectively utilize these available diagnostic tests in clinical practice.<xref rid="fsb220956-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="fsb220956-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="fsb220956-bib-0003" ref-type="bibr"><sup>3</sup></xref>
</p>
              <p>Here, we share our experience of SARS‚ÄêCoV‚Äê2 PCR sensitivity and separately obtained IgM, IgA, and IgG sensitivity of an in‚Äêhouse enzyme‚Äêlinked immunosorbent assay (ELISA) during the natural course of disease in a cohort of patients presenting to the hospital.</p>
            </sec>
            <sec sec-type="methods" id="fsb220956-sec-0002">
              <label>2</label>
              <title>METHODS</title>
              <sec id="fsb220956-sec-0003">
                <label>2.1</label>
                <title>Setting and design</title>
                <p>The project was conducted within the clinical laboratories of the Massachusetts General Hospital (MGH), a Clinical Laboratory Improvement Amendments‚Äêcertified laboratory. The study was designed as a single‚Äêcenter, retrospective review of PCR results and serology data. PCR results were obtained between 3 March 2020 and 15 April 2020 and we superimposed serology data obtained from confirmed COVID‚Äê19 positive patients as part of ongoing clinical validation studies of an ELISA for regulatory approval. The study was conducted with approval¬†from¬†the Mass General Brigham Institutional¬†Review Board.¬†We also used previously published data as a comparison dataset (W√∂lfel et al<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref>).</p>
              </sec>
              <sec id="fsb220956-sec-0004">
                <label>2.2</label>
                <title>PCR</title>
                <p>Nucleic acid testing was performed as part of clinical care at MGH using three real‚Äêtime PCR assays, each of which received EUA by the FDA. Our laboratory‚Äêdeveloped real‚Äêtime PCR assay uses the Centers for Disease Control and Prevention (CDC) primers targeting regions of the N gene of SARS‚ÄêCoV‚Äê2, the cobas SARS‚ÄêCoV‚Äê2 Test performed on the cobas 6800 (Roche) targets regions of the ORF1a and E genes, and the Xpert Xpress SARS‚ÄêCoV‚Äê2 assay run on the GeneXpert Infinity (Cepheid) targets regions of the N and E genes. Choice of which testing platform to use was determined by access to reagents available at the time of clinical testing provided for patient care. Our laboratory‚Äêdeveloped assay was validated to detect SARS‚ÄêCoV‚Äê2 at or above 5 copies/¬µL with 100% technical sensitivity and specificity. For commercial assays, we internally validated the assays and found 100% technical sensitivity and specificity. Within our validation cohort of known positive patients, we found 100% concordance between all three platforms. Despite excellent (technical) performance characteristics, pre‚Äêanalytical factors may decrease the performance of viral detection. These factors may include timing during the course of infection, improper sampling, specimen handling and others.</p>
              </sec>
              <sec id="fsb220956-sec-0005">
                <label>2.3</label>
                <title>Serology</title>
                <p>An in‚Äêhouse ELISA developed by Massachusetts General Hospital (Boston, MA) and the Ragon Institute of MGH, MIT, and Harvard (Cambridge, MA), was used to measure IgG, IgA, and IgM antibodies that target the SARS‚ÄêCoV‚Äê2 receptor binding domain (RBD) within the spike protein. The optical density (OD) was read at 450 and 570¬†nm on a plate reader. OD values were adjusted by subtracting the 570¬†nm OD from the 450¬†nm OD. To estimate antibody titers, we generated isotype‚Äêspecific standard curves using anti‚ÄêSARS‚ÄêCoV‚Äê1/2 monoclonal IgG, IgA, and IgM antibodies. We used this standard curve to calculate the concentration of anti‚ÄêRBD IgG, IgA, and IgM expressed in U/mL. Positive specimens were identified as those that had an U/mL three standard deviations above the mean of negative control specimens. (data not shown). The overall specificity was 98.6% for IgM, 99.0% for IgA, and 99.5% for IgG in 207 samples obtained before the pandemic (1 March 2019‚Äê14 January 2020) when no detectable antibody responses would be expected.</p>
              </sec>
              <sec id="fsb220956-sec-0006">
                <label>2.4</label>
                <title>Determination of date of symptom onset</title>
                <p>The date of symptom onset was determined by review of the electronic medical record by physician investigators. The onset date was determined in by one of two ways from the medical record: (a) as explicitly defined in the chart from an MD‚Äêwritten note as ‚ÄúCOVID‚Äê19+ date of symptom onset‚Äù or (b) determined from MD and non‚ÄêMD notes that stated date of symptom onset for any COVID‚Äê19‚Äìrelated symptom that developed acutely and was new from baseline (fever, chills, loss of smell or taste, body aches, fatigue, runny nose, congestion, sore throat, cough, and shortness of breath). Cases for which the date of symptom onset could not be determine were excluded from analysis (21/359, or 5.8%, of all PCR and serology cases).</p>
              </sec>
              <sec id="fsb220956-sec-0007">
                <label>2.5</label>
                <title>Patient cohorts and statistical analysis</title>
                <p>Clinical laboratory test results are stored in a laboratory information management system connected to the electronic medical record. We performed two data queries with different end‚Äêdates: an initial PCR‚Äêquery (3 March 2020 to 15 April 2020) and a second PCR‚Äêquery (3 March 2020 to 4 May 2020).</p>
                <p>The initial PCR‚Äêquery was performed to delineate clinical sensitivity over time, and analysis was restricted to patients with multiple PCR test results and at least one positive (ie, the most informative subset). These patients were considered confirmed COVID‚Äê19 positive and taken as true positives. All PCR test results regardless of specimen type were used to confirm a patient as SARS‚ÄêCoV‚Äê2 positive; however, only PCR test results from a NP‚Äêswab specimen were used for sensitivity calculations. The resulting dataset consists of 624 PCR results from 209 unique subjects. In this subset, 83% were inpatients, 13% were patients from the ED, and 4% were outpatients. For each specimen, we manually mapped date of symptom onset and all test results on a daily scale and calculated: (a) the time (in days) from the date of symptom onset to the date of specimen collection, (b) the duration from the first positive PCR test result to any subsequent positive PCR test result, and (c) clinical detection rates (PCR‚Äêpositive over total tests per day) at each day in relation to symptom onset or first PCR‚Äêpositive, respectively. We modeled a linear daily regression trend after first positive PCR test, to estimate the time when PCR sensitivity reaches zero (foot‚Äêpoint analysis).</p>
                <p>The second PCR query was performed to capture hospital‚Äêwide testing metrics, and to assess whether the above subset analysis of SARS‚ÄêCoV‚Äê2 patients with multiple PCR results is representative of the entire tested population in our setting. We extracted admission date, encounter, discharge date (when applicable), age, gender, and collection types and times, reporting dates and times along with results from all SARS‚ÄêCoV‚Äê2 PCR tests. By clinical encounter, 55.5% of orders originated in the outpatient setting, 12.1% originated in the emergency department (ED), and 32.2% of orders originated from the inpatient setting. The overall PCR positivity rate was 27.0% (n¬†=¬†3163/11¬†703) in unique individuals and 28.3% of all tests performed (n¬†=¬†4320/15¬†251; Table¬†<xref rid="fsb220956-tbl-0001" ref-type="table">1</xref>). All test results were used for calculations of test number over time, positivity rate and age as well as gender calculations (Figures¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
                <table-wrap position="float" id="fsb220956-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Demographics of cohorts used in analysis</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">PCR total</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">PCR‚Äêpositive</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">PCR multiple tests</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Serology</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">n (%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">n (%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">n (%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">n (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Patients</td>
                        <td align="left" rowspan="1" colspan="1">11¬†698</td>
                        <td align="left" rowspan="1" colspan="1">3163 (27)</td>
                        <td align="left" rowspan="1" colspan="1">209</td>
                        <td align="left" rowspan="1" colspan="1">157</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median</td>
                        <td align="left" rowspan="1" colspan="1">46</td>
                        <td align="left" rowspan="1" colspan="1">47</td>
                        <td align="left" rowspan="1" colspan="1">46<xref rid="fsb220956-note-0003" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">57<xref rid="fsb220956-note-0003" ref-type="table-fn">*</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Average</td>
                        <td align="left" rowspan="1" colspan="1">47.0</td>
                        <td align="left" rowspan="1" colspan="1">48.0</td>
                        <td align="left" rowspan="1" colspan="1">48.6</td>
                        <td align="left" rowspan="1" colspan="1">57</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Range</td>
                        <td align="left" rowspan="1" colspan="1">0 to 102</td>
                        <td align="left" rowspan="1" colspan="1">0 to 102</td>
                        <td align="left" rowspan="1" colspan="1">21 to 93</td>
                        <td align="left" rowspan="1" colspan="1">22 to 98</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gender</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">6411 (55)</td>
                        <td align="left" rowspan="1" colspan="1">1584 (25)</td>
                        <td align="left" rowspan="1" colspan="1">110 (53)<xref rid="fsb220956-note-0004" ref-type="table-fn">**</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">55 (35)<xref rid="fsb220956-note-0004" ref-type="table-fn">**</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">5270 (45)</td>
                        <td align="left" rowspan="1" colspan="1">1576 (30)</td>
                        <td align="left" rowspan="1" colspan="1">99 (47)</td>
                        <td align="left" rowspan="1" colspan="1">102 (65)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                        <td align="left" rowspan="1" colspan="1">22 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (14)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="fsb220956-ntgp-0002">
                    <title>Note</title>
                    <fn id="fsb220956-note-0002">
                      <p>PCR‚Äêpositive is the SARS‚ÄêCoV‚Äê2 PCR‚Äêpositive subset of the all tested patients (PCR Total). PCR Multiple Tests is a cohort of patients with¬†multiple PCR test results (and at least one positive result) used for clinical sensitivity analysis shown in Figure¬†<xref rid="fsb220956-fig-0001" ref-type="fig">1</xref>. Serology is an independent subset of PCR‚Äêpositive patients.</p>
                    </fn>
                    <fn id="fsb220956-note-0003">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic>¬†&lt;¬†.01 from student <italic toggle="yes">t</italic> test;</p>
                    </fn>
                    <fn id="fsb220956-note-0004">
                      <label>**</label>
                      <p><italic toggle="yes">P</italic>¬†&lt;¬†.01 from Fisher's exact test.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>To compare our data of mainly hospitalized patients to a population with mild disease, we used data derived from W√∂lfel et al,<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref> in which patients with a known exposure were instructed to present to the clinic at the first sign of symptoms. A positive PCR was necessary for inclusion into the study. We applied the validated limit of detection of our laboratory‚Äêdeveloped assay (5 copies/¬µL) to the data derived from W√∂lfel et al,<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref> and used the same calculations for time‚Äêdependent clinical sensitivity for PCR.</p>
                <p>Serologic analysis of IgM, IgA and IgG status was performed in a subset of the above SARS‚ÄêCoV‚Äê2 PCR‚Äêpositive patients for which we had excess material in the MGH core laboratories for clinical validation studies. For each sample, we determined the days post symptom onset at the collection date and calculated daily sensitivity for each antibody isotype as well as detection rate of any isotype. Although serology is currently considered a diagnostic aid (as opposed to a primary diagnostic test), we calculated sensitivity as the number of seropositive samples over the total number of tested samples from patients with the disease (ie, who tested positive by PCR).</p>
                <p>We plotted the sensitivity for both test modalities (PCR and serology) as percentages per overlapping 5‚Äêday leading intervals against the days since symptom onset. Statistical analysis consisted of Fisher's exact test (association of SARS‚ÄêCoV‚Äê2 status with dichotomous factors), <italic toggle="yes">œá</italic>
<sup>2</sup> with Yates correction, or <italic toggle="yes">t</italic> test (comparison of means).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="fsb220956-sec-0008">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="fsb220956-sec-0009">
                <label>3.1</label>
                <title>PCR sensitivity for SARS‚ÄêCoV‚Äê2 nucleic acid decreased with days post symptom onset</title>
                <p>SARS‚ÄêCoV‚Äê2 viral RNA levels decline over the course of infection.<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref> This decline of RNA levels clearly impacts the clinical sensitivity of PCR testing. It is not possible to determine the false negative rate of the PCR test from patients with a single PCR result. Therefore, we identified patients with multiple PCR tests who had at least one positive test result (considered true positives). The resulting dataset is composed of 624 test results from 209 patients (6.6% of all PCR‚Äêpositive patients, Table¬†<xref rid="fsb220956-tbl-0001" ref-type="table">1</xref>). We compared this subset to all tested patients (Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S1</xref>, Table¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S1</xref>) and contingency analysis of the multi‚ÄêPCR vs. all single PCR‚Äêpositive patient subset showed no significant differences in age, gender, and test type (Table¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S1</xref>, Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S2</xref>). Thus, we consider the multi‚ÄêPCR subset demographically representative of our tested patient population.</p>
                <p>To derive clinical sensitivity over disease course, we needed to define an anchor point. We chose two different anchor points: symptom onset (subjective) and first positive test (objective). First, we examined the time course by anchoring test results to the day of symptom onset (Figures¬†<xref rid="fsb220956-fig-0001" ref-type="fig">1</xref> and <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S3</xref>). Clinical sensitivity remains above 90% for the first 5¬†days after symptom onset. In our cohort of patients presenting to the hospital, patients were admitted to the hospital a median of 8¬†days after symptom onset (interquartile range: 4‚Äê16¬†days; mean: 10¬†days), and between Days 6 and 8, the clinical sensitivity of PCR ranged from 84% to 76%. On subsequent days the sensitivity decreases, and at Day 18 the sensitivity decreases below 50%. We also compared sensitivity data from an earlier study of mildly symptomatic patients<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref> and noted a steeper PCR sensitivity decline, consistent with viral levels dropping more quickly in this population (Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S4</xref>). This data provide sensitivity estimates at the time of presentation (eg, a patient presents at Day 10 after symptom onset). Second, we also modeled how PCR sensitivity decreases over time after the first positive PCR test (Figures¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S3</xref> and <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S5</xref>). Regression modeling and extension of PCR positivity decay (foot‚Äêpoint analysis) revealed that in our cohort, NP‚Äêswab specimens could stay PCR‚Äêpositive beyond 20 and up to 40¬†days (Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S5</xref>).</p>
                <fig position="float" fig-type="Figure" id="fsb220956-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>Sensitivity by assay modality over time. Blood‚Äêbased serologic sensitivity in 157 patients superimposed onto NP swab PCR data from 209 patients. Results for all patient samples from initial symptom onset are plotted: PCR‚Äî516, Serology‚Äî588 (196 samples¬†√ó¬†3 isotypes). Serology sensitivity is based on detection of IgM, IgG, or IgA. Sample results prior to Day 0 were excluded. PCR and serology samples were obtained in largely different patient populations; therefore, sensitivities are not additive. Data is plotted as 5‚Äêday moving average against the days since symptom onset. NA, none assessed</p>
                  </caption>
                  <graphic xlink:href="FSB2-34-13877-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="fsb220956-sec-0010">
                <label>3.2</label>
                <title>Serological assay sensitivity increases with days post symptom onset</title>
                <p>Seroconversion is also a dynamic response to the virus and assay sensitivity changes over time. To assess the sensitivity of our serology assay over time, we tested for IgM, IgG, and IgA antibodies against the RBD of SARS‚ÄêCoV‚Äê2 spike protein in 157 SARS‚ÄêCoV‚Äê2 PCR‚Äêpositive patients using an in‚Äêhouse ELISA (Table¬†<xref rid="fsb220956-tbl-0001" ref-type="table">1</xref>). For some patients, we were able to assess serology at multiple time points (n¬†=¬†591 total isotype tests on 197 total specimens). Anchoring our serologic results to days after symptom onset shows that seroconversion starts as early as symptom onset, is detectable in 50% of subjects after Day 7, and continues to increase with &gt;80% of patients showing seropositivity after Day 12 (Tables¬†<xref rid="fsb220956-tbl-0002" ref-type="table">2</xref> and <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S2</xref>; Figures¬†<xref rid="fsb220956-fig-0001" ref-type="fig">1</xref> and <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S4</xref>). In the subset of patients with multiple serological tests we saw isotype switching occur as short as 1‚Äê4¬†days, consistent with recent reports.<xref rid="fsb220956-bib-0005" ref-type="bibr"><sup>5</sup></xref> Of note, we detected IgA prior to IgM or IgG in a number of individuals, with two subjects having only detectable IgA within 3¬†days of symptom onset. We also documented cases of IgG positivity prior to IgM or IgA, highlighting the utility of measuring seroconversion using all three isotypes (Table¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S3</xref>, Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S6</xref>). The superimposition of serologic sensitivities with PCR sensitivities shows that, after Day 7, seroconversion is a reliable diagnostic aid indicating recent or prior infection (Figure¬†<xref rid="fsb220956-fig-0001" ref-type="fig">1</xref>).</p>
                <table-wrap position="float" id="fsb220956-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Sensitivity of anti‚ÄêSARS‚ÄêCoV‚Äê2 serology by isotype, age, gender, and days post symptom onset</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Total specimens tested</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">197</th>
                        <th align="left" rowspan="2" valign="bottom" colspan="1">%</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Male</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Female</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Age¬†&lt;¬†70</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Age¬†‚â•¬†70</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Days post symptom onset</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">n</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">(% male)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">(% female)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">(% &lt;70)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">(% ‚â•70)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>&lt;8¬†days (total)</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>60</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>39</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>21</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>34</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>26</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG</td>
                        <td align="char" char="." rowspan="1" colspan="1">9</td>
                        <td align="char" char="." rowspan="1" colspan="1">15</td>
                        <td align="left" rowspan="1" colspan="1">7 (18)</td>
                        <td align="left" rowspan="1" colspan="1">2 (10)</td>
                        <td align="left" rowspan="1" colspan="1">6 (18)</td>
                        <td align="left" rowspan="1" colspan="1">3 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM</td>
                        <td align="char" char="." rowspan="1" colspan="1">12</td>
                        <td align="char" char="." rowspan="1" colspan="1">20</td>
                        <td align="left" rowspan="1" colspan="1">9 (23)</td>
                        <td align="left" rowspan="1" colspan="1">3 (14)</td>
                        <td align="left" rowspan="1" colspan="1">9 (26)</td>
                        <td align="left" rowspan="1" colspan="1">3 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM or IgA</td>
                        <td align="char" char="." rowspan="1" colspan="1">15</td>
                        <td align="char" char="." rowspan="1" colspan="1">25</td>
                        <td align="left" rowspan="1" colspan="1">12 (31)</td>
                        <td align="left" rowspan="1" colspan="1">3 (14)</td>
                        <td align="left" rowspan="1" colspan="1">10 (28)</td>
                        <td align="left" rowspan="1" colspan="1">5 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>8 to 14¬†days (total)</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>85</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>58</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>27</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>70</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>15</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG</td>
                        <td align="char" char="." rowspan="1" colspan="1">45</td>
                        <td align="char" char="." rowspan="1" colspan="1">53</td>
                        <td align="left" rowspan="1" colspan="1">33 (57)</td>
                        <td align="left" rowspan="1" colspan="1">12 (44)</td>
                        <td align="left" rowspan="1" colspan="1">40 (57)</td>
                        <td align="left" rowspan="1" colspan="1">5 (33)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM</td>
                        <td align="char" char="." rowspan="1" colspan="1">53</td>
                        <td align="char" char="." rowspan="1" colspan="1">62</td>
                        <td align="left" rowspan="1" colspan="1">38 (66)</td>
                        <td align="left" rowspan="1" colspan="1">15 (56)</td>
                        <td align="left" rowspan="1" colspan="1">45 (64)</td>
                        <td align="left" rowspan="1" colspan="1">8 (53)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM or IgA</td>
                        <td align="char" char="." rowspan="1" colspan="1">58</td>
                        <td align="char" char="." rowspan="1" colspan="1">68</td>
                        <td align="left" rowspan="1" colspan="1">40 (69)</td>
                        <td align="left" rowspan="1" colspan="1">18 (67)</td>
                        <td align="left" rowspan="1" colspan="1">50 (71)</td>
                        <td align="left" rowspan="1" colspan="1">8 (53)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>&gt;14¬†days (total)</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>52</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>35</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>17</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>47</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>5</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG</td>
                        <td align="char" char="." rowspan="1" colspan="1">46</td>
                        <td align="char" char="." rowspan="1" colspan="1">88</td>
                        <td align="left" rowspan="1" colspan="1">30 (86)</td>
                        <td align="left" rowspan="1" colspan="1">16 (94)</td>
                        <td align="left" rowspan="1" colspan="1">42 (89)</td>
                        <td align="left" rowspan="1" colspan="1">4 (80)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM</td>
                        <td align="char" char="." rowspan="1" colspan="1">47</td>
                        <td align="char" char="." rowspan="1" colspan="1">90</td>
                        <td align="left" rowspan="1" colspan="1">31 (89)</td>
                        <td align="left" rowspan="1" colspan="1">16 (94)</td>
                        <td align="left" rowspan="1" colspan="1">43 (91)</td>
                        <td align="left" rowspan="1" colspan="1">4 (80)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive for IgG or IgM or IgA</td>
                        <td align="char" char="." rowspan="1" colspan="1">49</td>
                        <td align="char" char="." rowspan="1" colspan="1">94</td>
                        <td align="left" rowspan="1" colspan="1">33 (94)</td>
                        <td align="left" rowspan="1" colspan="1">16 (94)</td>
                        <td align="left" rowspan="1" colspan="1">45 (96)</td>
                        <td align="left" rowspan="1" colspan="1">4 (80)</td>
                      </tr>
                    </tbody>
                  </table>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="fsb220956-sec-0011">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>We present the dynamic clinical sensitivity of SARS‚ÄêCoV‚Äê2 PCR and our serology platform in patients presenting to the hospital. We performed this single‚Äêcenter, retrospective analysis to share real‚Äêworld evidence that can inform interpretation of PCR and serologic testing. We focused on assessing the clinical utility of both modalities in conjunction by direct superimposition of both sensitivity time courses. The direct superimposition shows that serology can function as a reliable diagnostic aid indicating recent or prior infection‚Äîin particular at times when PCR sensitivity is lower than 70%. Our findings emphasize that understanding the specific sensitivity kinetics of both modalities is paramount for interpretation and effective utilization of SARS‚ÄêCoV‚Äê2 diagnostics.</p>
              <p>There is considerable interest in moving SARS‚ÄêCoV‚Äê2 diagnostics to evidence‚Äêbased principles.<xref rid="fsb220956-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="fsb220956-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="fsb220956-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="fsb220956-bib-0009" ref-type="bibr"><sup>9</sup></xref> While clinicians await formal guidance from large, prospective, multi‚Äêcenter studies‚Äîwhich will be challenging during the ongoing pandemic‚Äîthere is considerable uncertainty surrounding SARS‚ÄêCoV‚Äê2 diagnostics in clinical practice.<xref rid="fsb220956-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="fsb220956-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="fsb220956-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="fsb220956-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="fsb220956-bib-0013" ref-type="bibr"><sup>13</sup></xref> Using available published data<xref rid="fsb220956-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="fsb220956-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="fsb220956-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="fsb220956-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="fsb220956-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="fsb220956-bib-0014" ref-type="bibr"><sup>14</sup></xref> and data presented here from our hospital, we offer the following five diagnostic principles for consideration:
<list list-type="order" id="fsb220956-list-0001"><list-item><p><bold>In symptomatic patients, all interpretations are anchored on days post symptom onset.</bold> Understanding performance characteristics of SARS‚ÄêCoV‚Äê2 diagnostics over the course of the infection is key to interpretation of results. We provide two distinct approaches to anchor interpretation over the course of infection: subjective (date of symptom onset) and objective (first PCR‚Äêpositive result). Both approaches are valid and have limitations. For example, the quality of patient histories is variable and in many cases the day of symptom onset is unknown or cannot easily be reconstructed. As a practical suggestion, to make this data easily obtainable and searchable, we recommend placing the date of symptom onset (when available) in the front page of the (electronic) medical record of patients diagnosed with COVID‚Äê19.</p></list-item><list-item><p><bold>PCR is the diagnostic gold standard during acute infection.</bold> PCR testing using consensus primers has an estimated specificity of &gt;99%.<xref rid="fsb220956-bib-0015" ref-type="bibr"><sup>15</sup></xref> Based on early reports from Wuhan<xref rid="fsb220956-bib-0016" ref-type="bibr"><sup>16</sup></xref> the overall clinical sensitivity is reported around 70%. We found a clinical sensitivity around 95% in the first 5¬†days after symptom onset and although PCR is an imperfect standard, concurrent IgM/IgA/IgG antibody assessment in the first 5¬†days post symptom onset does not significantly aid in rendering a current diagnosis; at no point during active infection should serology replace PCR for diagnosis.</p></list-item><list-item><p><bold>Clinical sensitivity of PCR decreases with days post symptom onset.</bold> In clinical practice many symptomatic patients present to medical care after Day 1 of symptom onset. Our data show PCR sensitivity decreases with days post symptom onset (Figure¬†<xref rid="fsb220956-fig-0001" ref-type="fig">1</xref>) and with days post first PCR‚Äêpositive test result (Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S5</xref>). Notably, some patients may have an initial PCR‚Äênegative result at presentation (Figure¬†<xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S3</xref>). Our data also indicate that severely ill patients (many patients in our cohort) remain PCR‚Äêpositive for a longer period than mildly ill patients (patients in the W√∂lfel et al<xref rid="fsb220956-bib-0004" ref-type="bibr"><sup>4</sup></xref> cohort Figure <xref rid="fsb220956-sup-0001" ref-type="supplementary-material">S4</xref>). Both time since symptom onset and disease severity may be key elements for the interpretation of PCR results.</p></list-item><list-item><p><bold>Serological assay sensitivity increases with days post symptom onset.</bold> By positivity alone, in our cohort, seropositivity surpasses PCR positivity after Days 8‚Äê10 post symptom onset. Remarkably, we find seroconversion does not follow the typical kinetics of IgM antibodies followed by class‚Äêswitched IgG and IgA antibodies. Rather, all appear simultaneously at a cohort level, with IgG or IgA seropositivity preceding IgM responses in some cases. Supporting this are other studies that report overall low IgM responses to SARS‚ÄêCoV‚Äê2 that are often preceded by IgG.<xref rid="fsb220956-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="fsb220956-bib-0017" ref-type="bibr"><sup>17</sup></xref> These data highlight the benefit of measuring all three anti‚ÄêSARS‚ÄêCoV‚Äê2 antibody isotypes to maximize sensitivity. In the case of SARS‚ÄêCoV‚Äê2, it is unknown for how long IgM, IgA, or IgG antibodies remain detectable after infection. It is important to note that a positive serologic result for IgM, IgA, and/or IgG does not conclusively indicate that a patient's presenting symptoms are due to a current SARS‚ÄêCoV‚Äê2 infection. Distinguishing a prior versus an acute infection by serology will require isotype‚Äêspecific interpretation, serial serologic testing to demonstrate seroconversion, and integration with clinical data.</p></list-item><list-item><p><bold>Negative results do not completely preclude SARS‚ÄêCoV‚Äê2 infection.</bold> Ruling out SARS‚ÄêCoV‚Äê2 infection remains challenging. Supplementing PCR results with serologic assessment can increase sensitivity (serology as a diagnostic aid). However, our data clearly show that there is a window period (Day 6‚Äê12 from symptom onset) when clinical sensitivity of PCR and serological assays are below 90%. In a symptomatic patient, if multiple PCR tests are negative and serological results after 8‚Äê12¬†days are also negative, we believe the likelihood of active SARS‚ÄêCoV‚Äê2 infection to be low. Clinical judgment is needed in this situation as there are rare scenarios where PCR negativity may be due to disease at a different anatomic site and/or serologic negativity may be due to an immunocompromised state.</p></list-item></list>
</p>
              <p>Limitations in our study include relatively small numbers, a retrospective design, and selection bias due to the specific setting and testing practice. We evaluated symptomatic, mostly hospitalized patients and we cannot derive recommendations for asymptomatic or mildly symptomatic patients from our data. Due to limited availability of tests and time constraints during an ongoing pandemic, we did not perform daily sampling. Date of symptom onset is not consistently available, subjective, and affected by recall biases‚Äîyet, it represents a useful anchor point for disease time course in symptomatic patients. Notably, the eclipse period ranges from 2 to 14¬†days<xref rid="fsb220956-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="fsb220956-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="fsb220956-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="fsb220956-bib-0021" ref-type="bibr"><sup>21</sup></xref> and some patients already mounted a serologic response at the time of presentation, which can be taken as an argument for the early y‚Äêaxis deviation from zero in the serology curve (Figure <xref rid="fsb220956-fig-0001" ref-type="fig">1</xref>) and a confirmation of date of symptom onset as an imperfect marker. We caution that the presented serology data are specific to our ELISA, and we cannot extrapolate to anti‚ÄêSARS‚ÄêCoV‚Äê2 antibody responses in general. Nonetheless, other publications indicate that the time courses are comparable.<xref rid="fsb220956-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="fsb220956-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="fsb220956-bib-0022" ref-type="bibr"><sup>22</sup></xref> Our serological studies measured antibodies to the RBD of SARS‚ÄêCoV‚Äê2. We chose this viral antigen because of its specificity to SARS‚ÄêCoV‚Äê2, and because anti‚ÄêRBD antibodies are typically neutralizing. Plaque reduction neutralization tests are the gold standard for assessing neutralizing ability,<xref rid="fsb220956-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="fsb220956-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="fsb220956-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="fsb220956-bib-0026" ref-type="bibr"><sup>26</sup></xref> and ongoing studies are in progress to confirm anti‚ÄêRBD antibodies are neutralizing in SARS‚ÄêCoV‚Äê2 infection.<xref rid="fsb220956-bib-0027" ref-type="bibr"><sup>27</sup></xref> Some commercially available assays measure the more abundant nucleocapsid protein, which may increase sensitivity to detect a serologic response early in the course of infection, therefore, shifting the seroconversion curve to the left. However, antibodies to nucleocapsid protein are unlikely to provide protective immunity as nucleocapsid protein is inaccessible to antibodies in an intact virus. Therefore, serology results also depend on the specific antigen employed in testing. Finally, our multi‚ÄêPCR cohort and serologic patient cohort are largely non‚Äêoverlapping PCR‚Äêpositive patients (n = 20/209). To enable additive sensitivity calculations from combined PCR and serology assays, prospective and systematically obtained repeated parallel PCR and quantitative serologic data will be necessary.</p>
              <p>Our real‚Äêworld data outline the strengths and weaknesses of two SARS‚ÄêCoV‚Äê2 test modalities over the natural course of infection. We hope these data, in conjunction with the five diagnostic principles for consideration, will contribute to effective utilization and interpretation of COVID‚Äê19‚Äìrelated laboratory data for patient care.</p>
            </sec>
            <sec sec-type="COI-statement" id="fsb220956-sec-0013">
              <title>CONFLICT OF INTEREST</title>
              <p>Dr Gelfand reports personal fees from Henry Schein Inc, outside the submitted work; Dr Turbett reports grants from Centers for Disease Control and Prevention, outside the submitted work; Dr Anahtar reports personal fees and other from Day Zero Diagnostics, outside the submitted work; Dr Ryan reports grants from CDC, during the conduct of the study. Dr. Branda reports grants from Zeus Scientific, grants from bioMerieux, grants from Immunetics, personal fees from T2 Biosystems, personal fees from DiaSorin, personal fees from Roche Diagnostics, grants from Bay Area Lyme Foundation, grants from Lyme Disease Biobank Foundation, outside the submitted work.</p>
            </sec>
            <sec id="fsb220956-sec-0014">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>T.E. Miller, W.F. Garcia Beltran, A.Z. Bard, T. Gogakos, E.S. Rosenberg, and J.K. Lennerz conceived and designed the study. T.E. Miller, W.F. Garcia Beltran, A.Z. Bard, T. Gogakos, M.N. Anahtar, M.G. Astudillo, D. Yang, J. Thierauf, A.S. Fisch, G.K. Mahowald, M.J. Fitzpatrick, V. Nardi, A. Dighe, R.C. Charles, E.T. Ryan, J.A. Branda, V.M. Pierce, M.R. Murali, A.J. Iafrate, E.S. Rosenberg, and J.K. Lennerz collected and assembled the data. T.E. Miller, W.F. Garcia Beltran, A.Z. Bard, T. Gogakos, M.N. Anahtar, V.M. Pierce, M.R. Murali, A.J. Iafrate, E.S. Rosenberg, and J.K. Lennerz analyzed and interpreted the data. T.E. Miller, W.F. Garcia Beltran, and J.K. Lennerz drafted the article. T.E. Miller, W.F. Garcia Beltran, A.Z. Bard, T. Gogakos, M.N. Anahtar, J.A. Gelfand, M.C. Poznansky, B.E. Bernstein, D.N. Louis, A. Dighe, R.C. Charles, E.T. Ryan, V.M. Pierce, M.R. Murali, A.J. Iafrate, E.S. Rosenberg, and J.K. Lennerz provided critical revisions and important intellectual content. All authors provided final approval of the article. J. Feldman, B.M. Hauser, T.M. Caradonna, G. Alter, A.G. Schmidt, J.B. Harris, R.C. Charles, and E.T. Ryan provided study materials or patients. J. Thierauf, H.D. Marble, L.L. Ritterhouse, S.E. Turbett, J. Batten, N.Z. Georgantas, D.N. Louis, and A. Dighe provided administrative, technical, or logistic support.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="fsb220956-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Supplementary Material</p>
                </caption>
                <media xlink:href="FSB2-34-13877-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="fsb220956-sec-0012">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors thank all patients and laboratory staff for making this study possible. CR3022 reference sequences, CR3022‚ÄêIgA and CR3022‚ÄêIgM isotypes, and ELISA protocols were kindly provided by Stephanie Fischinger, Caroline Atyeo, and Matthew Slein from the laboratory of Dr Galit Alter (Ragon Institute). We thank Yael Heher MD for excellent discussions. ELISA protocols were developed and optimized with the laboratory of Dr Alejandro Balazs (Ragon Institute). This work is also in part supported by NIH (RO1 CA225655) to JKL, Centers for Disease Control and Prevention U01CK000490 (ETR, RCC), NIGMS training grant T32 GM007753 (BMH, TMC), NIH R01 AI146779 (AGS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health or any other organization.</p>
            </ack>
            <ref-list content-type="cited-references" id="fsb220956-bibl-0001">
              <title>REFERENCES</title>
              <ref id="fsb220956-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0001"><string-name><surname>Cheng</surname><given-names>MP</given-names></string-name>, <string-name><surname>Papenburg</surname><given-names>J</given-names></string-name>, <string-name><surname>Desjardins</surname><given-names>M</given-names></string-name>, et al. <article-title>Diagnostic testing for severe acute respiratory syndrome‚Äêrelated coronavirus 2: a narrative review</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>(<issue>11</issue>):<fpage>726</fpage>‚Äê<lpage>734</lpage>.<pub-id pub-id-type="pmid">32282894</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0002"><string-name><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name><surname>Ren</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S</given-names></string-name>, et al. <article-title>Profiling early humoral response to diagnose novel coronavirus disease (COVID‚Äê19)</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>71</volume>(<issue>15</issue>):<fpage>778</fpage>‚Äê<lpage>785</lpage>.<pub-id pub-id-type="pmid">32198501</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0003"><string-name><surname>Sethuraman</surname><given-names>N</given-names></string-name>, <string-name><surname>Jeremiah</surname><given-names>SS</given-names></string-name>, <string-name><surname>Ryo</surname><given-names>A</given-names></string-name>. <article-title>Interpreting diagnostic tests for SARS‚ÄêCoV‚Äê2</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>22</issue>):<fpage>2249</fpage>.<pub-id pub-id-type="pmid">32374370</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0004"><string-name><surname>Wolfel</surname><given-names>R</given-names></string-name>, <string-name><surname>Corman</surname><given-names>VM</given-names></string-name>, <string-name><surname>Guggemos</surname><given-names>W</given-names></string-name>, et al. <article-title>Virological assessment of hospitalized patients with COVID‚Äê2019</article-title>. <source>Nature</source>. <year>2020</year>;<volume>581</volume>(<issue>7809</issue>):<fpage>465</fpage>‚Äê<lpage>469</lpage>.<pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0005"><string-name><surname>He</surname><given-names>X</given-names></string-name>, <string-name><surname>Lau</surname><given-names>EHY</given-names></string-name>, <string-name><surname>Wu</surname><given-names>P</given-names></string-name>, et al. <article-title>Temporal dynamics in viral shedding and transmissibility of COVID‚Äê19</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>5</issue>):<fpage>672</fpage>‚Äê<lpage>675</lpage>.<pub-id pub-id-type="pmid">32296168</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0006"><string-name><surname>Nicola</surname><given-names>M</given-names></string-name>, <string-name><surname>O'Neill</surname><given-names>N</given-names></string-name>, <string-name><surname>Sohrabi</surname><given-names>C</given-names></string-name>, <string-name><surname>Khan</surname><given-names>M</given-names></string-name>, <string-name><surname>Agha</surname><given-names>M</given-names></string-name>, <string-name><surname>Agha</surname><given-names>R</given-names></string-name>. <article-title>Evidence based management guideline for the COVID‚Äê19 pandemic ‚Äê review article</article-title>. <source>Int J Surg</source>. <year>2020</year>;<volume>77</volume>:<fpage>206</fpage>‚Äê<lpage>216</lpage>.<pub-id pub-id-type="pmid">32289472</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0007"><string-name><surname>Pascarella</surname><given-names>G</given-names></string-name>, <string-name><surname>Strumia</surname><given-names>A</given-names></string-name>, <string-name><surname>Piliego</surname><given-names>C</given-names></string-name>, et al. <article-title>COVID‚Äê19 diagnosis and management: a comprehensive review</article-title>. <source>J Intern Med</source>. <year>2020</year>;<volume>288</volume>(<issue>2</issue>):<fpage>192</fpage>‚Äê<lpage>206</lpage>.<pub-id pub-id-type="pmid">32348588</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0008"><string-name><surname>Tang</surname><given-names>YW</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>JE</given-names></string-name>, <string-name><surname>Persing</surname><given-names>DH</given-names></string-name>, <string-name><surname>Stratton</surname><given-names>CW</given-names></string-name>. <article-title>Laboratory diagnosis of COVID‚Äê19: current issues and challenges</article-title>. <source>J Clin Microbiol</source>. <year>2020</year>;<volume>58</volume>(<issue>6</issue>):<fpage>e00512</fpage>‚Äê<lpage>e00520</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00512-20</pub-id>
<pub-id pub-id-type="pmid">32245835</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0009"><string-name><surname>Weissleder</surname><given-names>R</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name><surname>Ko</surname><given-names>J</given-names></string-name>, <string-name><surname>Pittet</surname><given-names>MJ</given-names></string-name>. <article-title>COVID‚Äê19 diagnostics in context</article-title>. <source>Sci Transl Med</source>. <year>2020</year>;<volume>12</volume>(<issue>546</issue>):<elocation-id>eabc1931</elocation-id>.<pub-id pub-id-type="pmid">32493791</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0010"><string-name><surname>Bermingham</surname><given-names>WH</given-names></string-name>, <string-name><surname>Wilding</surname><given-names>T</given-names></string-name>, <string-name><surname>Beck</surname><given-names>S</given-names></string-name>, <string-name><surname>Huissoon</surname><given-names>A</given-names></string-name>. <article-title>SARS‚ÄêCoV‚Äê2 serology: test, test, test, but interpret with caution!</article-title><source>Clin Med</source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):<fpage>365</fpage>‚Äê<lpage>368</lpage>.</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0011"><string-name><surname>Cevik</surname><given-names>M</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>CGG</given-names></string-name>, <string-name><surname>Ho</surname><given-names>A</given-names></string-name>. <article-title>COVID‚Äê19 pandemic‚Äêa focused review for clinicians</article-title>. <source>Clin Microbiol Infect</source>. <year>2020</year>;<volume>26</volume>(<issue>7</issue>):<fpage>842</fpage>‚Äê<lpage>847</lpage>.<pub-id pub-id-type="pmid">32344166</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0012"><string-name><surname>Pulia</surname><given-names>MS</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>TP</given-names></string-name>, <string-name><surname>Hou</surname><given-names>PC</given-names></string-name>, <string-name><surname>Schuman</surname><given-names>A</given-names></string-name>, <string-name><surname>Sambursky</surname><given-names>R</given-names></string-name>. <article-title>Multi‚Äêtiered screening and diagnosis strategy for COVID‚Äê19: a model for sustainable testing capacity in response to pandemic</article-title>. <source>Ann Med</source>. <year>2020</year>;<volume>52</volume> (<issue>5</issue>):<fpage>207</fpage>‚Äê<lpage>214</lpage>.<pub-id pub-id-type="pmid">32370561</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0013"><string-name><surname>Weinstein</surname><given-names>MC</given-names></string-name>, <string-name><surname>Freedberg</surname><given-names>KA</given-names></string-name>, <string-name><surname>Hyle</surname><given-names>EP</given-names></string-name>, <string-name><surname>Paltiel</surname><given-names>AD</given-names></string-name>. <article-title>Waiting for certainty on Covid‚Äê19 antibody tests ‚Äê at what cost?</article-title><source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>6</issue>):<elocation-id>e37</elocation-id>.<pub-id pub-id-type="pmid">32501664</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0014"><string-name><surname>Long</surname><given-names>QX</given-names></string-name>, <string-name><surname>Liu</surname><given-names>BZ</given-names></string-name>, <string-name><surname>Deng</surname><given-names>HJ</given-names></string-name>, et al. <article-title>Antibody responses to SARS‚ÄêCoV‚Äê2 in patients with COVID‚Äê19</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>:<fpage>845</fpage>‚Äê<lpage>848</lpage>.<pub-id pub-id-type="pmid">32350462</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0015"><string-name><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Sakthivel</surname><given-names>SK</given-names></string-name>, et al. <article-title>US CDC Real‚Äêtime reverse transcription pcr panel for detection of severe acute respiratory syndrome coronavirus 2</article-title>. <source>Emerg Infect Dis</source>. <year>2020</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1654</fpage>‚Äê<lpage>1665</lpage>.</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0016"><string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gao</surname><given-names>R</given-names></string-name>, et al. <article-title>Detection of SARS‚ÄêCoV‚Äê2 in different types of clinical specimens</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>18</issue>):<fpage>1843</fpage>‚Äê<lpage>1844</lpage>.<pub-id pub-id-type="pmid">32159775</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0017"><string-name><surname>Qu</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, et al. <article-title>Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‚ÄêCoV‚Äê2)</article-title> [published online ahead of print, <year>2020</year>]. <source>Clin Infect Dis</source>. <pub-id pub-id-type="doi">10.1093/cid/ciaa489</pub-id>
</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0018"><string-name><surname>Backer</surname><given-names>JA</given-names></string-name>, <string-name><surname>Klinkenberg</surname><given-names>D</given-names></string-name>, <string-name><surname>Wallinga</surname><given-names>J</given-names></string-name>. <article-title>Incubation period of 2019 novel coronavirus (2019‚ÄênCoV) infections among travellers from Wuhan, China</article-title>. <source>Eurosurveillance</source>. <year>2020</year>;<volume>25</volume>(<issue>5</issue>):<fpage>20</fpage>‚Äê<lpage>28</lpage>.</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0019"><string-name><surname>Lauer</surname><given-names>SA</given-names></string-name>, <string-name><surname>Grantz</surname><given-names>KH</given-names></string-name>, <string-name><surname>Bi</surname><given-names>Q</given-names></string-name>, et al. <article-title>The incubation period of coronavirus disease 2019 (COVID‚Äê19) from publicly reported confirmed cases: estimation and application</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>(<issue>9</issue>):<fpage>577</fpage>‚Äê<lpage>582</lpage>.<pub-id pub-id-type="pmid">32150748</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0020"><string-name><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name><surname>Guan</surname><given-names>X</given-names></string-name>, <string-name><surname>Wu</surname><given-names>P</given-names></string-name>, et al. <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus‚Äêinfected pneumonia</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>13</issue>):<fpage>1199</fpage>‚Äê<lpage>1207</lpage>.<pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0021"><string-name><surname>Linton</surname><given-names>NM</given-names></string-name>, <string-name><surname>Kobayashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data</article-title>. <source>J Clin Med</source>. <year>2020</year>;<volume>9</volume>(<issue>2</issue>):<elocation-id>538</elocation-id>.</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0022"><string-name><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H</given-names></string-name>, et al. <article-title>Antibody responses to SARS‚ÄêCoV‚Äê2 in patients of novel coronavirus disease 2019</article-title> [published online ahead of print, <year>2020</year>]. <source>Clin Infect Dis</source>. <pub-id pub-id-type="doi">10.1093/cid/ciaa344</pub-id>
</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0023"><string-name><surname>Brouwer</surname><given-names>PJM</given-names></string-name>, <string-name><surname>Caniels</surname><given-names>TG</given-names></string-name>, <string-name><surname>van der Straten</surname><given-names>K</given-names></string-name>, et al. <article-title>Potent neutralizing antibodies from COVID‚Äê19 patients define multiple targets of vulnerability</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>(<issue>6504</issue>):<fpage>643</fpage>‚Äê<lpage>650</lpage>.<pub-id pub-id-type="pmid">32540902</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0024"><string-name><surname>He</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, et al. <article-title>Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)‚Äêassociated coronavirus: importance for designing SARS vaccines</article-title>. <source>Virology</source>. <year>2005</year>;<volume>334</volume>(<issue>1</issue>):<fpage>74</fpage>‚Äê<lpage>82</lpage>.<pub-id pub-id-type="pmid">15749124</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0025"><string-name><surname>Rogers</surname><given-names>TF</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name><surname>Huang</surname><given-names>D</given-names></string-name>, et al. <article-title>Isolation of potent SARS‚ÄêCoV‚Äê2 neutralizing antibodies and protection from disease in a small animal model</article-title> [published online ahead of print, <year>2020</year>]. <source>Science</source>. <pub-id pub-id-type="doi">10.1126/science.abc7520</pub-id>
</mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0026"><string-name><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>W</given-names></string-name>, et al. <article-title>Potent neutralization of SARS‚ÄêCoV‚Äê2 by human antibody heavy‚Äêchain variable domains isolated from a large library with a new stable scaffold</article-title>. <source>mAbs</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>1778435</elocation-id>.<pub-id pub-id-type="pmid">32544372</pub-id></mixed-citation>
              </ref>
              <ref id="fsb220956-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="fsb220956-cit-0027"><string-name><surname>Ju</surname><given-names>B</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Ge</surname><given-names>X</given-names></string-name>, et al. <article-title>Potent human neutralizing antibodies elicited by SARS‚ÄêCoV‚Äê2 infection</article-title>. <source>bioRxiv</source>. 2020.03.21.990770. <year>2020</year>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
